Logos Global Management LP Amends Olema Pharma Stake

TL;DR

Logos Global Management LP updated their stake in Olema Pharmaceuticals. Keep an eye on this.

AI Summary

Logos Global Management LP, through Derek Gould, has amended its Schedule 13D filing regarding Olema Pharmaceuticals, Inc. The amendment, filed on June 6, 2024, indicates a change in beneficial ownership. Logos Global Management LP is based in San Francisco, CA.

Why It Matters

This filing signals a potential shift in significant ownership or strategy for Olema Pharmaceuticals, which could impact its stock price and future corporate actions.

Risk Assessment

Risk Level: medium — Changes in beneficial ownership filings can precede significant corporate events or shifts in investor sentiment, warranting close monitoring.

Key Players & Entities

• Logos Global Management LP (company) — Filing entity
• Derek Gould (person) — Authorized to receive notices
• Olema Pharmaceuticals, Inc. (company) — Subject company
• 780 BRANNAN STREET, SAN FRANCISCO, CA 94103 (address) — Olema Pharmaceuticals business address
• 1 LETTERMAN DRIVE, BLDG C, SUITE C3-350, SAN FRANCISCO, CA 94129 (address) — Logos Global Management LP business address

FAQ

Key Financial Figures

• $0.0001 — ame of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securiti
• $14.85 — en market on Nasdaq for a sale price of $14.85 per share, or $10,395,000. Logos Fund I
• $10,395,000 — or a sale price of $14.85 per share, or $10,395,000. Logos Fund I continues to hold 700,761
• $3,301,775.60 — 1 shares of the Stock for which it paid $3,301,775.60 in cash from its working capital. On J
• $7,053,750 — or a sale price of $14.85 per share, or $7,053,750. Logos Fund II continues to hold 708,11
• $7,833,369.50 — 4 shares of the Stock for which it paid $7,833,369.50 in cash from its working capital. Logo
• $29,389,432 — 0 shares of the Stock for which it paid $29,389,432 in cash from its working capital. Item

Filing Documents

• olma13ga2.htm (SC 13D/A) — 68KB
• 0000935836-24-000426.txt ( ) — 69KB

Security and Issuer

Item 1. Security and Issuer This Amendment No. 2 (this “Amendment”) to Schedule 13D relates to shares of Common Stock, par value $0.0001 per share (the “Stock”), of Olema Pharmaceuticals, Inc. (the “Issuer”), and amends and supplements the initial statement on Schedule 13D and the Schedule 13D Amendment no. 1 (collectively, the “Schedule 13D”) filed by Logos Global Management LP (“Logos Global”), Logos Opportunities GP LLC (“Logos Opportunities GP”), Logos GP LLC (“Logos GP”), Logos Global Management GP LLC (“Logos Global GP”), Arsani William and Graham Walmsley (collectively, the “Filers”) on December 3, 2020 and November 28, 2023 respectively. The principal executive office of the Issuer is located at 780 Brannan Street, San Francisco, California 94103 . Except as provided herein, this Amendment No. 2 to Schedule 13D does not modify any of the information previously reported on such Schedule 13D. The information herein is provided and is correct as of June 4, 2024. Unless otherwise indicated, each capitalized term used but not defined herein shall have the meaning assigned to such term in such Schedule 13D as originally filed.

Source and Amount of Funds or Other Consideration

Item 3. Source and Amount of Funds or Other Consideration

is hereby supplemented by adding the

Item 3 is hereby supplemented by adding the following sentences: On June 4, 2024, Logos Opportunities Fund I LP (the “Logos Fund I”) sold 700,000 shares of the Stock in the open market on Nasdaq for a sale price of $14.85 per share, or $10,395,000. Logos Fund I continues to hold 700,761 shares of the Stock for which it paid $3,301,775.60 in cash from its working capital. On June 4, 2024, Logos Opportunities Fund II LP (the “Logos Fund II”) sold 475,000 shares of the Stock in the open market on Nasdaq for a sale price of $14.85 per share, or $7,053,750. Logos Fund II continues to hold 708,114 shares of the Stock for which it paid $7,833,369.50 in cash from its working capital. Logos Global Master Fund LP continues to hold 1,825,000 shares of the Stock for which it paid $29,389,432 in cash from its working capital.

Interest in Securities of the Issuer

Item 5. Interest in Securities of the Issuer

of the Schedule 13D is hereby replaced

Item 5 of the Schedule 13D is hereby replaced as follows: Percentage interests in shares of Common Stock reported in this Amendment are based on 55,933,827 shares of Stock outstanding as of May 3, 2024, as reported in the Form 10-Q filed by the Issuer on May 8, 2024. (a) See the cover page for each Filer. (b) See the cover page for each Filer. (c) On June 4, 2024, Logos Fund I sold 700,000 shares of the Stock in the open market on Nasdaq for a sale price of $14.85 per share, or $10,395,000 and Logos Fund II sold 475,000 shares of the Stock in the open market on Nasdaq for a sale price of $14.85 per share, or $7,053,750. The Filers have not engaged in any other transactions in the Issuer’s securities in the 60 days preceding the date of this Amendment to Schedule 13D. (d) Not applicable. (e) Logos Opportunities GP and Logos GP ceased to be the beneficial owners of more than five per cent of the Stock on June 4, 2024; otherwise not applicable.

Material to Be Filed as Exhibits

Item 7. Material to Be Filed as Exhibits Exhibit AAgreement Regarding Joint Filing of Statement on Schedule 13D or 13G. Exhibit B Amended and Restated Investor Rights Agreement among the Issuer, Opportunities I, Opportunities II and certain other stockholders, attached as Exhibit 4.2 to the Issuer’s Form S-1 Registration Statement (No. 333-249748), filed on October 30, 2020, and incorporated herein by reference to the Schedule 13D. Exhibit CStock Purchase Agreement, dated September 5, 2023, by and among the Issuer and the Purchasers named therein, attached as Exhibit 10.1 to the Issuer’s Form 8-K filed on September 5, 2023. 8 CUSIP No. 60862P106

SIGNATURES

SIGNATURES After reasonable inquiry and to the best of my knowledge, I certify that the information set forth in this statement is true, complete and correct. Dated:June 6, 2024 /s/ Arsani William Arsani William /s/ Graham Walmsley Graham Walmsley Logos Global Management LP By: /s/ Arsani William Name: Arsani William Title: Managing Partner Logos Opportunities GP LLC By: /s/ Arsani William Name: Arsani William Title: Managing Member Logos Global Management GP LLC By: /s/ Arsani William Name: Arsani William Title: Managing Member Logos GP LLC By: /s/ Arsani William Name: Arsani William Title: Managing Member 9 CUSIP No. 60862P106 EXHIBIT A AGREEMENT REGARDING JOINT FILING OF STATEMENT ON SCHEDULE 13D OR 13G The undersigned agree to file jointly with the Securities and Exchange Commission (the “SEC”) any and all statements on Schedule 13D, Schedule 13G or forms 3, 4 or 5 (and any amendments or supplements thereto) required under section 13(d) or 16(a) of the Securities Exchange Act of 1934, as amended, in connection with purchases by the undersigned of the securities of any issuer. For that purpose, the undersigned hereby constitute and appoint Logos Global Management LP, a Delaware limited partnership, as their true and lawful agent and attorney-in-fact, with full power and authority for and on behalf of the undersigned to prepare or cause to be prepared, sign, file with the SEC and furnish to any other person all certificates, instruments, agreements and documents necessary to comply with section 13(d) and section 16(a) of the Act, in connection with said purchases, and to do and perform every act necessary and proper to be done incident to the exercise of the foregoing power, as fully as the undersigned might or could do if personally present. Dated:June 6, 2024 /s/ Arsani William Arsani William /s/ Graham Walmsley Graham Walmsley Logos Global Management LP By: /s/ Arsani William Name: Arsa

View Full Filing

View this SC 13D/A filing on SEC EDGAR